…
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug discovery platform that integrates the technologies to synthesize highly diverse macrocyclic peptide libraries and screen for hit compounds, as well as enables rapid and efficient identification of novel hit compounds with high potency and selectivity for protein targets in drug discovery campaigns. It is developing 64Cu-ATSM indicated for malignant brain tumor; and 177Lu/64Cu-PSMA I&T indicated for prostate cancer that are in phase 3 clinical phase development stage, as well as GhR Antagonist indicated for acromegaly that is in phase 2 clinical phase development stage. The company also develops 225Ac/68Ga-GPC3 indicated for hepatocellular carcinoma; 177Lu/68Ga-FAP indicated for pancreatic, lung, breast, colon cancer; 225Ac/64Cu-CA9 indicated for renal cell carcinoma; 18F-PD-L1 indicated for cancer; CD38-ARM indicated for multiple myeloma; S2-protein inhibitors indicated for COVID-19; and merck that are in phase 1 clinical phase development stage. In addition, it develops novartis and rayzeBio indicated for cancer, 225Ac/64Cu-CLDN18.2 indicated for stomach cancer, 225Ac/177Lu/64Cu/68Ga-CDH3 indicated for head and neck cancer, KIT inhibitors indicated for allergic diseases, oral myostatin inhibitors indicated for obesity/muscle disease, and Oral IL-17A/F inhibitors indicated for inflammatory diseases such as psoriasis that are currently under preclinical development stage. Further, the company involved in research, development, manufacture and sale of pharmaceuticals in the fields of radiopharmaceuticals (RI) and non-RI. PeptiDream Inc. was incorporated in 2006 and is based in Kawasaki, Japan.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
PeptiDream Inc is a Japan-based biotechnology company that leverages a proprietary peptide discovery platform to generate peptide drug candidates and to support partnered programs with pharmaceutical companies. Long-term growth may be driven by licensing and milestone revenues from collaborations, progression of its internal pipeline, and wider adoption of its discovery platform, which could support recurring partnership income.
Material risks include clinical and regulatory failure of its drug candidates, dependence on milestone and licensing payments with partner concentration, and limited liquidity and disclosure associated with its OTC Pink listing.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -5316.76M | 20888.81M | 4353.47M | 6653.32M | 4823.65M |
| Net income | -3752.48M | 15014.92M | 3035.83M | 7554.36M | 3606.41M |
| Selling general administrative | 7473.92M | 6845.00M | 7256.19M | 6220.62M | - |
| Selling and marketing expenses | - | 1743.00M | - | - | - |
| Gross profit | 7528.91M | 34503.82M | 17218.72M | 18113.49M | 7007.95M |
| Reconciled depreciation | 2126.51M | 2248.47M | 2433.18M | 1973.38M | 633.01M |
| Ebit | -4978.82M | 21547.70M | - | 8965.97M | 4368.97M |
| Ebitda | -2850.46M | 23796.17M | - | 10939.35M | 5001.97M |
| Depreciation and amortization | 2128.37M | 2248.47M | - | 1973.38M | 633.01M |
| Operating income | -4978.82M | 21113.84M | 6773.05M | 8980.20M | 4418.14M |
| Other operating expenses | 23516.22M | 25562.68M | - | 17872.23M | 4947.82M |
| Interest expense | 500.75M | 658.89M | 2253.01M | 2312.64M | 0.00M |
| Tax provision | -1562.92M | 5873.88M | 1317.64M | -901.03M | 1217.24M |
| Interest income | 242.61M | 411.24M | 190.98M | 189.05M | 0.28M |
| Net interest income | -257.70M | -247.65M | -2062.03M | -2123.60M | 0.12M |
| Income tax expense | -1564.29M | 5873.88M | - | -901.03M | 1217.24M |
| Total revenue | 18537.40M | 46676.52M | 28712.19M | 26852.43M | 9365.96M |
| Total operating expenses | 12507.73M | 13389.98M | 21939.15M | 9133.29M | 2589.81M |
| Cost of revenue | 11008.48M | 12172.70M | 11493.48M | 8738.94M | 2358.01M |
| Total other income expense net | -337.94M | -225.04M | - | -2326.87M | 405.51M |
| Net income from continuing ops | -3749.20M | 15014.92M | 3035.83M | 7554.36M | 3606.41M |
| Net income applicable to common shares | - | - | - | 7554.36M | 3606.41M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 77100.41M | 92769.83M | 69464.01M | 63865.20M | 26619.17M |
| Intangible assets | 2018.51M | 2142.97M | 2211.45M | 2232.55M | 75.50M |
| Other current assets | 1157.11M | 1130.91M | 335.96M | 550.96M | 255.12M |
| Total liab | 25527.18M | 36007.53M | 29114.30M | 31823.74M | 1620.57M |
| Total stockholder equity | 51573.23M | 56762.30M | 40349.71M | 32041.47M | 24998.60M |
| Other current liab | 1129.65M | 2442.46M | 712.84M | 4259.65M | 1170.81M |
| Common stock | 3960.19M | 3956.74M | - | 3956.74M | 3956.74M |
| Capital stock | 3956.74M | 3956.74M | 3956.74M | 3956.74M | 3956.74M |
| Retained earnings | 45626.58M | 49393.47M | 27804.69M | 23848.34M | 17543.27M |
| Other liab | - | - | - | 2435.53M | 348.89M |
| Good will | 8377.98M | 8370.68M | 8370.68M | 8370.68M | - |
| Other assets | - | 0.00M | - | 0.00M | 0.00M |
| Cash | 28707.96M | 48117.93M | 19507.86M | 5247.66M | 11746.53M |
| Total current liabilities | 23438.98M | 18406.77M | 8617.09M | 11030.40M | 1271.68M |
| Current deferred revenue | 995.84M | - | - | 3367.32M | - |
| Net debt | -11651.58M | -28483.49M | 2712.84M | 15800.78M | -11746.53M |
| Short term debt | 17056.38M | 2592.93M | - | 2690.65M | - |
| Short long term debt | 17041.51M | 2592.93M | 2586.26M | 2690.65M | - |
| Short long term debt total | 17056.38M | 19634.45M | - | 21048.45M | - |
| Other stockholder equity | 1987.13M | 3412.09M | - | 4236.39M | 3498.59M |
| Property plant equipment | - | - | - | 18125.42M | 6437.15M |
| Total current assets | 38953.79M | 57209.63M | 27225.08M | 25072.71M | 13863.30M |
| Net tangible assets | - | - | - | 21438.23M | 24923.09M |
| Short term investments | 6.25M | 6.25M | 6.25M | 6.24M | - |
| Net receivables | 5895.36M | 5282.89M | 4970.86M | 16589.15M | 936.51M |
| Long term debt | 0.00M | 17041.51M | 19634.45M | 18357.80M | - |
| Inventory | 3193.35M | 2671.66M | 2404.16M | 2678.70M | 925.14M |
| Accounts payable | 4257.10M | 5332.04M | 3203.56M | 4080.10M | 100.87M |
| Accumulated other comprehensive income | -771.93M | - | - | - | - |
| Non currrent assets other | 93.16M | 2771.21M | 46.85M | 112.91M | 6149.25M |
| Non current assets total | 38146.62M | 35560.19M | 42238.93M | 38792.49M | 12755.86M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -300.00M | 10558.46M | 1302.54M | -27377.22M | -798.04M |
| Change to liabilities | - | - | - | 1453.71M | 45.59M |
| Total cashflows from investing activities | -2055.79M | 8370.79M | - | -27377.22M | -2283.45M |
| Net borrowings | -2640.00M | -2640.00M | 1160.00M | 21002.42M | 21002.42M |
| Total cash from financing activities | -4061.25M | -2994.63M | - | 20789.45M | 66.07M |
| Change to operating activities | - | - | - | 2096.30M | -751.93M |
| Net income | -3752.48M | 20888.81M | 3035.83M | 6653.32M | 4823.65M |
| Change in cash | -19293.46M | 28610.07M | 14260.20M | -6498.86M | 4597.17M |
| Begin period cash flow | 48001.43M | 138.25M | 5247.66M | 11746.53M | 7149.36M |
| End period cash flow | 28707.96M | 306.03M | 19507.86M | 5247.66M | 11746.53M |
| Total cash from operating activities | -13288.46M | 23844.99M | 12420.97M | -82.93M | 6654.71M |
| Issuance of capital stock | 0.00M | 18.75M | - | 0.00M | 44.94M |
| Depreciation | 2128.37M | 2248.47M | 2433.18M | 1973.38M | 633.01M |
| Other cashflows from investing activities | 0.80M | -111.17M | - | -10.51M | -276.97M |
| Change to inventory | -519.36M | -267.50M | 274.54M | -656.49M | -339.16M |
| Change to account receivables | -584.94M | -312.03M | - | -11286.61M | 4844.64M |
| Sale purchase of stock | -961.75M | -0.16M | -514.55M | -0.17M | -0.36M |
| Other cashflows from financing activities | -389.82M | -354.75M | - | 22469.62M | 21.49M |
| Change to netincome | - | - | - | -1217.58M | -1384.01M |
| Capital expenditures | 1644.37M | 2218.27M | 1368.96M | 3975.42M | 1214.68M |
| Change in working capital | -2153.60M | 1107.37M | 10813.44M | -10385.53M | 4616.29M |
| Other non cash items | -9510.75M | -399.66M | -1421.73M | 1675.90M | -3418.24M |
| Free cash flow | -14932.83M | 21626.72M | 11052.01M | -4058.34M | 5440.03M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| PPTDF PeptiDream Inc |
- -% |
6.70 | - | 41.32 | 0.05 | 2.84 | 6.69 | 8.88 |
| NVO Novo Nordisk A/S |
-1.06 2.73% |
37.81 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.64 1.08% |
515.02 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
920.69 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug discovery platform that integrates the technologies to synthesize highly diverse macrocyclic peptide libraries and screen for hit compounds, as well as enables rapid and efficient identification of novel hit compounds with high potency and selectivity for protein targets in drug discovery campaigns. It is developing 64Cu-ATSM indicated for malignant brain tumor; and 177Lu/64Cu-PSMA I&T indicated for prostate cancer that are in phase 3 clinical phase development stage, as well as GhR Antagonist indicated for acromegaly that is in phase 2 clinical phase development stage. The company also develops 225Ac/68Ga-GPC3 indicated for hepatocellular carcinoma; 177Lu/68Ga-FAP indicated for pancreatic, lung, breast, colon cancer; 225Ac/64Cu-CA9 indicated for renal cell carcinoma; 18F-PD-L1 indicated for cancer; CD38-ARM indicated for multiple myeloma; S2-protein inhibitors indicated for COVID-19; and merck that are in phase 1 clinical phase development stage. In addition, it develops novartis and rayzeBio indicated for cancer, 225Ac/64Cu-CLDN18.2 indicated for stomach cancer, 225Ac/177Lu/64Cu/68Ga-CDH3 indicated for head and neck cancer, KIT inhibitors indicated for allergic diseases, oral myostatin inhibitors indicated for obesity/muscle disease, and Oral IL-17A/F inhibitors indicated for inflammatory diseases such as psoriasis that are currently under preclinical development stage. Further, the company involved in research, development, manufacture and sale of pharmaceuticals in the fields of radiopharmaceuticals (RI) and non-RI. PeptiDream Inc. was incorporated in 2006 and is based in Kawasaki, Japan.
| Name | Title | Year Born |
|---|---|---|
| Dr. Patrick Crawford Reid Ph.D. | Pres, CEO & Representative Director | 1975 |
| Dr. Kiyofumi Kaneshiro Ph.D. | CFO, Exec. VP & Director | NA |
| Dr. Keiichi Masuya Ph.D. | COO, Exec. VP & Director | 1969 |
| Toshiyuki Iwata | Head of Investor Relations | NA |
| Yuko Okimoto | Exec. Officer of IR PR Department | NA |
| Dr. Patrick Crawford Reid Ph.D. | President, CEO & Representative Director | 1975 |
| Ms. Kaseri Oura M.S., P.M.P. | Executive Vice President of Operations | 1975 |
| Mr. Christian Cunningham Ph.D. | Chief Scientific Officer | NA |
| Ms. Yuko Okimoto | IR & Public Relations Director | NA |
| Mr. Kodo Shikata Ph.D. | Executive Vice President of People & Culture | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.